HOME >> BIOLOGY >> NEWS
What's next for gene therapy? Plastic

Blacksburg, Va., Sept. 13, 2006 -- Gene therapy depends upon foreign DNA, even viruses, to deliver genes, therapeutic proteins, or medicine to cells within the body. Many scientists are looking for better chaperones across the cell membrane. Virginia Tech researchers think polymer molecules can be created to do the job.

The research will be presented at the 232nd national meeting of the American Chemical Society in San Francisco September 10-14, 2006.

"We are applying our fundamental knowledge in polymer science to gene transfer agents," said Tim Long, professor of chemistry in the College of Science at Virginia Tech. "We are trying to understand how the structure of the chaperone impacts the efficiency of its ability to transfer DNA across the cell membrane."

Entire texts have been devoted to the subject, Long said. "But the researchers are usually biologists. Polymer scientists can bring a unique perspective that I think will lead to new advances."

Long's graduate student, John M. Layman of Richmond, Va., will share information regarding star-shaped, or highly-branched, molecules, which are extremely effective at transfection. Long's group has demonstrated that the topology of these particular polymers can be changed. "We can control the molecular shape and number of functional end groups," said Long. "We think that topology is important because it can influence the strength of the interaction with DNA and permit efficient release of the DNA for protein synthesis."

Layman will deliver the talk, "Influence of macromolecular architecture on nucleic acid transfection (POLY 611)," at 4 p.m., Wednesday, Sept. 13, in the Marriott Salon 14/15 as part of the International Biorelated Polymers Symposium. Authors are Layman, Anjali A. Hirani of the Virginia Tech-Wake Forest School of Biomedical Engineering (VT-WF SBES), Joseph M. Pickel and Phillip F. Britt of the Oak Ridge National Laboratory Chemical Sciences Division,
'"/>

Contact: Susan Trulove
STrulove@vt.edu
540-231-5646
Virginia Tech
13-Sep-2006


Page: 1 2

Related biology news :

1. Whats the backscatter of your beer?
2. Whats going on in the body? Advanced time-of-flight PET takes a superior look
3. Whats in the water? Estrogenic activity documented in fish caught in Pittsburghs rivers
4. A Cross-Disciplinary Look at Scientific Truth: Whats the Law to Do?
5. Whats the difference between mice and men?
6. Ossur repeats Popular Science Best of Whats New award
7. Whats shaped like a pear and has two genomes? Check the pond
8. Whats nature worth? New computer models tell all
9. HPV Vaccine: Whats next
10. Anti-evolutionism in AmericaWhats ahead?
11. Ossurs Power Knee wins Popular Science magazines 2005 Best of Whats New Award

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: What next for gene therapy Plastic

(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
(Date:11/21/2014)... Nov. 20, 2014   Atmel® Corporation (NASDAQ: ... (MCU) and touch technology solutions, today launched the industry,s ... with the widest V cc range from 1.7V ... and faster I 2 C bus communication speeds, and ... memory making them ideal for consumer, industrial, computer, and ...
(Date:11/18/2014)... , Nov. 17, 2014   ... and EMC collaborate to develop The Partners Data ... , The Partners Data Lake will allow researcher ... improve diagnostics, treatment and the lives of patients ... research and clinical activities across the Partners system, ...
Breaking Biology News(10 mins):Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 2Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 3Atmel Launches Industry's First Wide-V(cc) Low-Power Temperature Sensor Family 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
(Date:12/17/2014)... ROCKVILLE, Md. , Dec. 17, 2014 ... biopharmaceutical company dedicated to the acquisition, development and commercialization ... needs for the global market with a primary commercial ... that it has been granted a Type C meeting ... that the meeting will be held in February 2015.  ...
(Date:12/15/2014)... Israel , Dec. 15, 2014  BrainStorm ... leading developer of adult stem cell technologies for neurodegenerative ... Ltd. was awarded a grant of approximately $1.1 million ... Chief Scientist (OCS).  This is the eighth year that ... the Office of the Chief Scientist, which is part ...
(Date:12/15/2014)...  Ascendis Pharma A/S, a biotechnology company that ... unmet medical needs, today announced positive six-month interim ... to evaluate once-weekly TransCon Growth Hormone in children ... analysis consists of 25 patients, representing approximately 50% ... completing all six months of treatment. ...
(Date:12/13/2014)... The DNA Microarray market market was ... expected to grow at a CAGR of 15.2% ... TOC of the DNA Microarray for an in-depth ... help of various tables and figures. , ... consists of instrument, consumables, and services, where the ...
Breaking Biology Technology:CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 2BrainStorm Receives $1,100,000 for its 8th Annual Non-Dilutive Grant from Israel's Chief Scientist Office 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Six-Month Interim Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 2DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 3DNA Microarray Market Is Expected to Grow at a CAGR of 15.2% from 2014 to 2019 - A Report by MicroMarket Monitor 4
Cached News: